Zhejiang Orient Gene Biotech Co., Ltd.: history, ownership, mission, how it works & makes money

Founded in December 2005 and listed on the STAR Market in February 2020 under ticker 688298, Zhejiang Orient Gene Biotech Co., Ltd. has grown from an R&D-focused manufacturer into a global in vitro diagnostics player whose products reach over 100 countries and whose overseas sales once accounted for about 95% of revenue; the company leveraged investments in POCT rapid diagnostics, molecular diagnostics and liquid biochips to secure more than 300 overseas certifications, over 70 domestic registrations, upwards of 1,000 authorized patents and over 2,200 medical device certifications worldwide, and became a major COVID-19 test exporter contributing roughly 16% of China's export volume for such reagents, while operating a wholly owned U.S. arm, Healgen Scientific LLC, and pursuing capital actions including a June-September 2025 equity buyback plan of up to 50 million yuan; meanwhile its integrated value chain-from raw materials through hundreds of POCT reagents across infectious disease, drugs of abuse, fertility, cardiac and tumor markers to diagnostic instruments-generated 827.92 million yuan in revenue for 2024 (a 0.95% increase year-over-year) even as the company recorded a net loss of 529 million yuan and held a market capitalization of 5.01 billion yuan as of December 2, 2025.

Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS): Intro

• Established: December 2005
• Listing: STAR Market, Shanghai Stock Exchange - Feb 2020 (688298.SS)
• Core focus: IVD reagents, POCT rapid diagnostics, molecular diagnostics, liquid biochips

• Global footprint by 2019: sales network in over 120 countries and regions
• Overseas revenue concentration (2019): ~95% of total revenue from international sales
• COVID-19 response (2020-2021): manufacturer of test reagents accounting for ~16% of China's total export volume of COVID-19 test kits

• Product sales: rapid diagnostic test kits (lateral flow assays), molecular RT-PCR reagents, antigen/antibody kits, and related consumables-sold direct, via distributors and through tenders.
• Export-driven revenue: high international penetration with the majority of sales coming from overseas markets (≈95% in 2019).
• Platform-driven R&D: investment in POCT, molecular diagnostics and liquid biochip platforms creates product families that scale across markets and regulatory regimes.
• Regulatory & certification advantage: >300 overseas and >70 domestic certifications lower market-entry friction and enable large-volume global procurement contracts.

• Integrated R&D-to-manufacturing: in-house development of reagent formulation, device design and production lines to control COGS and ensure supply chain reliability.
• Quality credentials: extensive domestic and international certifications that facilitate entry into public health tenders and private healthcare channels worldwide.
• Surge capacity: ramped manufacturing during the COVID-19 pandemic to capture significant export share (~16% of China's exported COVID-19 test kits) and meet global demand spikes.

• POCT rapid diagnostics: lateral-flow immunoassays and cassette-based devices targeting infectious diseases and biomarker screening.
• Molecular diagnostics: RT-PCR kits and related reagents for pathogen detection used in labs and point-of-care settings.
• Liquid biochips: multiplex testing capabilities for panels and surveillance applications.

• Overseas certifications: >300
• Domestic registration certificates: >70
• International presence: sales network in >120 countries and regions (2019)

Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS): History

• Public listing: Shanghai Stock Exchange STAR Market (Ticker: 688298.SS).
• Shareholder mix: institutional investors, retail/individual shareholders, and company insiders-providing a diversified capital base.
• International footprint: wholly-owned U.S. subsidiary Healgen Scientific LLC (Houston, Texas) supports distribution and regulatory engagement in North America.
• Corporate action example: equity buyback announced to reinforce capital management and shareholder returns.

• Strategic implications: the 2025 buyback (RMB 50M) signals management confidence, improves capital allocation flexibility, and can support EPS and market confidence during strategic expansion.
• Global strategy: Healgen bolsters U.S. market access, regulatory alignment, and distribution channels, aligning with the company's export and R&D ambitions.

Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS): Ownership Structure

• Mission: Research, development, production and sales of in vitro diagnostic products to enhance global health through innovative medical solutions.
• Technology focus: Emphasis on applying cutting-edge genetic engineering and molecular technologies to lead in high-end medical equipment and devices.
• Platform industrialization: Accelerate commercialization of core platforms - POCT rapid diagnostics, molecular diagnostics, and liquid biochips.
• Global reach: Products exported to over 100 countries and regions to improve international healthcare access.
• Quality and IP: More than 1,000 authorized patents and over 2,200 product medical device certifications worldwide.
• Core values: Innovation, quality, global health enhancement - guiding strategic decisions and operations.

Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS): Mission and Values

• Integrated value chain: in-house raw material production (antibodies, colloidal gold, nitrocellulose membranes), assembly of lateral-flow and instrument-enabled assays, and distribution/logistics for finished POCT products.
• Product breadth: a flagship POCT rapid-diagnostics portfolio spanning five core categories - infectious diseases, drugs of abuse, pregnancy & fertility, cardiac markers, and tumor markers - with the company offering hundreds of rapid diagnostic SKUs.
• Global commercialization: subsidiary Healgen Scientific LLC drives development, manufacturing and international commercialization of in vitro diagnostic systems to expand global penetration and regulatory registrations.
• R&D-driven pipeline: ongoing investment in next-generation rapid assays, multiplexing, immunoassay formats and instrument integration to meet changing market and public-health needs.

• POCT rapid diagnostic kits - primary revenue driver, sold to clinical labs, hospitals, public-health agencies, NGOs and retail channels.
• Diagnostic instruments - complementary products that enable quantitative or semi-quantitative reporting and support recurring consumable kit sales.
• Raw materials and OEM production - supplying antibodies, membranes and components to internal production and external partners.
• International distributor network and Healgen subsidiary sales - expansion and registration in target markets to convert local demand into recurring orders.

• Export footprint: products sold to more than 100 countries and regions.
• Overseas sales contribution: approximately 95% of total sales are reported to come from overseas markets, highlighting heavy reliance on international distribution.
• Distribution channels: direct subsidiary (Healgen), regional distributors, public procurement contracts, humanitarian and emergency-response sales.

• High-margin consumables: repeat purchases of single-use rapid-test kits constitute recurring revenue and margin stability.
• Instrument attachment: sale of instruments creates ecosystem lock-in for kits and generates service/support revenue.
• OEM and raw-materials sales: vertical integration captures upstream margin and reduces supply risk.
• Geographic diversification: global sales and Healgen's localized registrations convert regional demand into sustained procurement contracts.
• R&D commercialization: new assays and regulatory approvals enable entry into new indications and tenders.

• R&D orientation: sustained investment to expand assay panels, develop multiplex/quantitative formats and accelerate regulatory filings in key markets.
• Quality systems: manufacturing under examples of ISO/CE/other regulatory frameworks as required per market (required for export-heavy model).
• Regulatory access strategy: leveraging Healgen and local distributors to achieve country-specific registrations and procurement eligibility.

Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS): How It Works

• Core product categories: infectious disease rapid tests, drugs-of-abuse assays, fertility tests, tumor marker kits, and cardiac marker assays.
• Channel mix: direct OEM/ODM supply, branded product sales through domestic and international distributors, and platform/instrument sales paired with consumable reagents.
• Globalization: direct overseas subsidiaries and partners (notably Healgen Scientific LLC) plus a distributor network serving hospitals, clinics, laboratories, public health programs and retail/consumer channels in dozens of countries.

• Product sales: recurring revenue from single-use POCT consumables (reagents, test strips) that require repeat purchase.
• Instrument/platform sales: one-time or periodic revenue from diagnostic readers and supporting hardware sold to clinics and labs.
• OEM/ODM contracts: contracted manufacturing and private-label supply for third-party customers, diversifying order flow.
• Geographic mix: strong export orientation-historically very high overseas proportion-reduces reliance on any single market.
• New product and regulatory pipeline: ongoing investment in R&D to expand test menu and achieve approvals (CE, select national registrations) supporting future sales.

• High-margin consumables model: instruments drive installations; consumables generate steady, repeatable margins.
• Scale manufacturing: in-house production enables cost control and rapid response to demand swings (epidemics, public-health campaigns).
• Channel diversification: mix of distributor partnerships, direct sales and subsidiary-led commercialization (Healgen) to access developed markets.
• Product diversification by diagnostic category reduces single-product risk and taps multiple clinical use-cases.

Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS): How It Makes Money

• Core revenue streams: sales of rapid test kits (antigen/antibody), molecular diagnostic kits (PCR/NAAT), immunoassay reagents, OEM manufacturing services, and recurring consumables.
• Channels: direct hospital/institution procurement, government tenders, international distributors, and OEM partnerships.
• Monetization drivers: product launches, scale manufacturing, regulatory approvals (CE/WHO/EUA where applicable), and distribution expansions.

• Market position & future outlook: maintains a significant position in the global IVD market through broad export reach; intends to expand product portfolio, bolster R&D capabilities, and deepen global penetration to restore profitability and capture emerging diagnostic demand.
• Strategic signals: the mid-2025 equity buyback demonstrated board-level confidence in long-term value despite the 2024 net loss, indicating a focus on shareholder value and balance-sheet optimization.
• Operational priorities to drive revenue: product diversification (molecular & point-of-care), higher-margin consumables, scaling OEM contracts, and seeking regulatory clearances to access new markets.